Supercharge Your Innovation With Domain-Expert AI Agents!

Pd-1 / pd-l1 inhibitors for cancer treatment

A PD-L1, PD-1 technology, applied in the direction of medical preparations containing active ingredients, antibody medical ingredients, anti-animal/human immunoglobulin, etc., can solve the problem of death, long-lasting and complete response of aRCC patients is uncommon, patient resistance to

Inactive Publication Date: 2019-01-11
MERCK PATENT GMBH +1
View PDF20 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, despite the dramatic improvement in patient outcomes with these agents, durable and complete responses are uncommon in patients with aRCC; most patients eventually develop resistance, develop disease progression during treatment, and die due to metastatic disease. die

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pd-1 / pd-l1 inhibitors for cancer treatment
  • Pd-1 / pd-l1 inhibitors for cancer treatment
  • Pd-1 / pd-l1 inhibitors for cancer treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0178] This example is about an open-label, multicenter, three-arm phase III clinical trial testing avelumab in combination with and / or after platinum-based chemotherapy in patients with previously untreated ovarian cancer.

[0179] The primary objective was to demonstrate that the use of avelumab in combination with and / or after frontline chemotherapy was superior to chemotherapy alone by centrally reviewing progression-free survival (PFS). Inclusion criteria included newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer after cytoreductive surgery or before neoadjuvant chemotherapy, regardless of PD-L1 status. The chemotherapy regimen allows the choice of weekly (80mg / m2) or Q3W (175mg / m2) paclitaxel and Q3W (once every two weeks) carboplatin. Approximately 951 eligible patients will be randomized to receive chemotherapy followed by observation; chemotherapy followed by avelumab; or a combination of chemotherapy and avelumab followed b...

Embodiment 2

[0181] This example is about a phase Ib clinical trial testing avelumab in patients with metastatic renal cell carcinoma.

[0182] Eligible patients had histologically demonstrated mRCC with a clear-cell component, measurable disease, archival / fresh tumor biopsy available, and an ECOG performance score of 0-1. Initial patients also required failure of 1 systemic therapy for mRCC. Patients received avelumab 10 mg / kg (1 hour intravenous infusion) Q2W until confirmed progression, unacceptable toxicity, or discontinuation. Tumors were assessed every 6 weeks by RECIST 1.1 and adverse events (AEs) were graded by NCI-CTCAE v4.0.

[0183] As of data cutoff, 19 patients had received avelumab for a median of 20 weeks (range 2-32) and had a follow-up of ≥13 weeks. The median age was 69 years (range 30-80), and 15 patients (78.9%) were male. The median time since metastatic diagnosis was 14.7 months, and patients with advanced disease received a median of 1 prior line of therapy (range...

Embodiment 3

[0186] This example relates to a phase I pharmacokinetic-pharmacodynamic study of avelumab in previously treated advanced classical Hodgkin's lymphoma.

[0187] The study is a Phase 1b dose-finding study designed to evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of avelumab in adult patients with cHL. Patients recruited for the study were those who had failed first-line salvage chemotherapy regimens. Treatment groups will explore the factors of nominal dose, frequency of administration, and weight-based versus fixed doses. Of the imported data, a total of N=30 patients will be randomized (1:1) among the 5 treatment groups. Up to 3 treatment arms will be expanded in dose expansion, where N=36 additional patients will be randomized (1:1). Selection criteria for the dose-expansion cohort included: safety, achievement of >90% mean target occupancy (TO), and observation of objective responses confirmed by ≥3 per malignant lymphoma response crit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.

Description

[0001] The present invention relates to a method for treating cancer in a subject, which comprises administering a therapeutically effective amount of an inhibitor of the interaction between PD-1 receptor and its ligand PD-L1 to the subject. Background technique [0002] cancer [0003] Cancer is an abnormal growth of cells that tend to proliferate in an uncontrolled manner, and in some cases metastasize (spread). Cancer is not a disease. It is a group of more than 100 different and unique disorders. Cancer can involve any tissue of the body and takes many different forms in every body region. Most cancers are named for the type of cell or organ in which they start. If the cancer spreads (metastases), the new tumor has the same name as the original (primary) tumor. The frequency of a particular cancer can depend on sex. While skin cancer is the most common type of malignancy in both men and women, the second most common type in men is prostate cancer and in women it is b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61P35/00
CPCA61K2039/505A61K2039/545C07K2317/21C07K2317/76C07K2317/90C07K2317/94C07K16/2827A61P35/04A61P35/00A61K45/06C07K2317/565
Inventor D·纳伊特恩A·莫罗佐夫A·伍尔夫松A·塔尔K·钦S·布拉尔
Owner MERCK PATENT GMBH
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com